Patents by Inventor Yechezkel Barenholz

Yechezkel Barenholz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10842745
    Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: November 24, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel Barenholz, Rivka Cohen
  • Patent number: 10722599
    Abstract: Provided are modified lipid compounds and their use in the formation of lipid assemblies. Also provided are lipid assemblies including (a) an amphoteric lipid including in covalent association with (i) one or more acyl chains; (ii) one or more weak base moiety; (iii) one or more weak acid moiety; the lipid assembly also including (b) one or more additional lipids, at least one of which being a zwitterionic lipid. In some embodiments, the amphoteric lipid is a compound including (a) a tri-functional moiety; (b) two non-phosphate lipid chains associated with two of the functional moieties of said tri-functional moiety; (c) optionally a spacer moiety associated with the third of the functional moieties of said tri-functional moiety; and (d) a polyalkylamine optionally including a short peptide with one to several carboxylic acid residues. Further provided are the uses of the lipid assembly, inter alia, for transfection or cancer treatment.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: July 28, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel Barenholz, Rivka Cohen, Kirill Makedonski, Eylon Yavin, Andreas Ingemann Jensen, Keren Turjeman
  • Publication number: 20200170948
    Abstract: The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20° C. to about 39° C. and the joint has a joint temperature which is above the phase transition temperature.
    Type: Application
    Filed: August 21, 2018
    Publication date: June 4, 2020
    Inventors: Yechezkel BARENHOLZ, Yaniv DOLEV, Keren TURJEMAN, Gadi SARFATI, Maty Ayal HERSHKOVITZ
  • Publication number: 20190374647
    Abstract: Liposomes with an entrapped amphipathic weak base and alkyl or aryl sulfonate are described as well as methods of making and using these liposomes.
    Type: Application
    Filed: June 13, 2019
    Publication date: December 12, 2019
    Inventors: Yechezkel BARENHOLZ, Tal BERMAN, Doron FRIEDMAN
  • Publication number: 20190151243
    Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
    Type: Application
    Filed: January 22, 2019
    Publication date: May 23, 2019
    Inventors: Yechezkel Barenholz, Rivka Cohen
  • Patent number: 10085940
    Abstract: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as ?? T-cells.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: October 2, 2018
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., KINGS COLLEGE LONDON, SHAARE ZEDEK SCIENTIFIC LTD.
    Inventors: Alberto A. Gabizon, Yechezkel Barenholz, Hilary Shmeeda, John Maher, Ana Catarina Parente Pereira
  • Patent number: 10052387
    Abstract: Based on the observation that the application of small amounts of exogenous acid sphingomyelinase to generate endogenous ceramide, or provision of exogenous long-chain natural C16-ceramide resulted in rapid translocation of vacuolar daunorubicin into the nucleus in multi-drug resistant (MDR) cells, the present invention relates to a nano-liposomal preparation that includes C16-ceramide. Exposure of MDR cells to the C16:0 ceramide-based nanoliposomes provide a mechanism to reverse MDR in chemoresistant cells and tumors, by inducing rapid translocation of chemotherapeutic agent from cytoplasmic vesicles to the nucleus.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: August 21, 2018
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, Yissum Research Development Company of the Hebrew University LTD
    Inventors: Richard Kolesnick, Yechezkel Barenholz, Erez Koren
  • Patent number: 10004688
    Abstract: Provided are liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions including the liposomes and methods of using them. The liposomes include a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: June 26, 2018
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel Barenholz, Amiram Goldblum, Ahuva Cern
  • Publication number: 20180043036
    Abstract: Provided are modified lipid compounds and their use in the formation of lipid assemblies. Also provided are lipid assemblies including (a) an amphoteric lipid including in covalent association with (i) one or more acyl chains; (ii) one or more weak base moiety; (iii) one or more weak acid moiety; the lipid assembly also including (b) one or more additional lipids, at least one of which being a zwitterionic lipid. In some embodiments, the amphoteric lipid is a compound including (a) a tri-functional moiety; (b) two non-phosphate lipid chains associated with two of the functional moieties of said tri-functional moiety; (c) optionally a spacer moiety associated with the third of the functional moieties of said tri-functional moiety; and (d) a polyalkylamine optionally including a short peptide with one to several carboxylic acid residues. Further provided are the uses of the lipid assembly, inter alia, for transfection or cancer treatment.
    Type: Application
    Filed: February 4, 2016
    Publication date: February 15, 2018
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., QBI Enterprises Ltd., Rosetta Genomics, Biolab Ltd.
    Inventors: Sharon AVKIN-NACHUM, Tirtsa KLEINMAN, Noga YERUSHALMI, Yechezkel BARENHOLZ, Rivka COHEN, Kirill MAKEDONSKI, Eylon YAVIN, Andreas Ingemann JENSEN, Keren TURJEMAN
  • Publication number: 20170281540
    Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
    Type: Application
    Filed: June 19, 2017
    Publication date: October 5, 2017
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem, LTD.
    Inventors: Yechezkel Barenholz, Rivka Cohen
  • Patent number: 9713591
    Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
    Type: Grant
    Filed: October 11, 2009
    Date of Patent: July 25, 2017
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, LTD.
    Inventors: Yechezkel Barenholz, Rivka Cohen
  • Publication number: 20170027869
    Abstract: Provided are liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions including the liposomes and methods of using them. The liposomes include a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.
    Type: Application
    Filed: April 8, 2015
    Publication date: February 2, 2017
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel BARENHOLZ, Amiram GOLDBLUM, Ahuva CERN
  • Patent number: 9078812
    Abstract: The present invention provides methods for desensitization for prevention or diminishing hypersensitivity reactions including C activation-related pseudoallergy (CARPA) and other reactions to particulate medicines. The desensitization is performed via pretreatment using a drug-free vehicle or carrier to eliminate or diminish the clinical symptoms of hypersensitivity.
    Type: Grant
    Filed: December 7, 2008
    Date of Patent: July 14, 2015
    Assignees: The Bay Zoltan Foundation for Applied Research, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel Barenholz, Janos Szebeni, Miklos Toth, Laszlo Rosivall
  • Publication number: 20150093434
    Abstract: Provided are pharmaceutical compositions including a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between ?2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between ?2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.
    Type: Application
    Filed: December 4, 2014
    Publication date: April 2, 2015
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUSALEM
    Inventors: Yechezkel BARENHOLZ, Alberto A. GABIZON, Yuval AVNIR
  • Publication number: 20150037404
    Abstract: A method for lubricating a joint of a mammal by administering into a cavity of the joint a composition of liposomes that are multilamellar vesicles (MLV) dispersed in a fluid medium, the liposomes having a mean diameter of between about 0.8 ?m to about 10 ?m and including membranes of at least one glycerophospholipid (GPL) having two C12-C16 hydrocarbon chains which are the same or different. These membranes have a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being at a temperature of about 20° C. to about 39° C. and being lower than the temperature of the joint.
    Type: Application
    Filed: October 22, 2014
    Publication date: February 5, 2015
    Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Yechezkel BARENHOLZ, Dorit NITZAN, Izhak ETSION, Avi SCHROEDER, Grigory HALPERIN, Sarit SIVAN
  • Patent number: 8932627
    Abstract: The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between ?2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between ?2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.
    Type: Grant
    Filed: September 11, 2005
    Date of Patent: January 13, 2015
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Yechezkel Barenholz, Alberto A. Gabizon, Yuval Avnir
  • Publication number: 20150004219
    Abstract: Liposomes with an entrapped amphipathic weak base and alkyl or aryl sulfonate are described as well as methods of making and using these liposomes.
    Type: Application
    Filed: February 3, 2013
    Publication date: January 1, 2015
    Inventors: Yechezkel Barenholz, Tal Berman, Doron Friedman
  • Patent number: 8895054
    Abstract: The present invention concerns methods of joint lubrication and/or prevention of cartilage wear making use of liposomes having membranes with at least one phospholipid (PL) of the group consisting of a glycerophospholipid (GPL) having two, being the same or different, C12-C16 hydrocarbon chain and a sphingolipid (SPL) having a C12-C15 hydrocarbon chain, the one or more membranes having a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being within a temperature of about 20° C. to about 39° C. for lubrication of joints.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: November 25, 2014
    Assignees: Technion Research and Development Foundation Ltd., Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Yechezkel Barenholz, Dorit Nitzan, Izhak Etsion, Avi Schroeder, Grigory Halperin, Sarit Sivan
  • Publication number: 20140328899
    Abstract: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as ?? T-cells.
    Type: Application
    Filed: July 7, 2012
    Publication date: November 6, 2014
    Applicants: SHAARE ZEDEK MEDICAL CENTER, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Alberto A. Gabizon, Yechezkel Barenholz, Hilary Shmeeda
  • Patent number: 8871276
    Abstract: The present invention discloses a dried composition comprising ?-casein micelles, assemblies and complexes thereof. The dried composition is stable in the dried state as well as upon re-suspension The dried composition retains the biological activity, drug load capacity, particle size and particle size distribution of the ?-casein micelles, assemblies and complexes comprising the active pharmaceutical ingredient, within the dried state and upon resuspension in a buffer or an aqueous pharmaceutical carrier.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: October 28, 2014
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Yechezkel Barenholz, Dganit Danino